Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
AKTX

Akari Therapeutics

$6.40

-0.08 (-1.23%)

09:12
10/18/17
10/18
09:12
10/18/17
09:12
Syndicate
Akari Therapeutics 3.48M share Spot Secondary priced at $5.00 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

AKTX

Akari Therapeutics

$6.40

-0.08 (-1.23%)

08:17
10/18/17
10/18
08:17
10/18/17
08:17
Technical Analysis
Technical View: Akari Therapeutics drops on $17M ADS secondary offering »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

IBM

IBM

$146.54

-0.29 (-0.20%)

, IBKR

Interactive Brokers

$47.40

-0.32 (-0.67%)

17:32
10/17/17
10/17
17:32
10/17/17
17:32
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: IBM…

IBM

IBM

$146.54

-0.29 (-0.20%)

IBKR

Interactive Brokers

$47.40

-0.32 (-0.67%)

SSKN

Strata Skin Sciences

$1.75

-0.04 (-2.23%)

HCLP

Hi-Crush Partners

$8.95

0.25 (2.87%)

SCSS

Ticker changed to SNBR

$30.38

-0.17 (-0.56%)

NAVI

Navient

$12.20

0.47 (4.01%)

CREE

Cree

$29.34

0.06 (0.20%)

AKTX

Akari Therapeutics

$6.40

-0.08 (-1.23%)

MOBL

MobileIron

$3.80

-0.1 (-2.56%)

FOGO

Fogo De Chao

$12.05

0.1 (0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 22

    Oct

  • 01

    Nov

  • 15

    Nov

  • 18

    Oct

AKTX

Akari Therapeutics

16:02
10/17/17
10/17
16:02
10/17/17
16:02
Syndicate
Akari Therapeutics files to sell common stock, no amount given »

Cantor Fitzgerald &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

$6.03

0.3 (5.24%)

07:09
10/11/17
10/11
07:09
10/11/17
07:09
Hot Stocks
Akari Therapeutics completes enrollment in COBALT Phase II PNH trial of Coversin »

Akari Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

$8.74

3.15 (56.35%)

08:13
09/22/17
09/22
08:13
09/22/17
08:13
Upgrade
Akari Therapeutics rating change at William Blair »

Akari Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AKTX

Akari Therapeutics

$5.59

-0.14 (-2.44%)

07:11
09/21/17
09/21
07:11
09/21/17
07:11
Hot Stocks
Akari Therapeutics plans to advance Coversin towards Phase III studies »

Akari Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AKTX

Akari Therapeutics

07:08
08/21/17
08/21
07:08
08/21/17
07:08
Hot Stocks
Akari Therapeutics names David Horn Solomon as CEO, effective Aug. 28 »

Akari Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
AKTX

Akari Therapeutics

16:34
08/18/17
08/18
16:34
08/18/17
16:34
Syndicate
Breaking Syndicate news story on Akari Therapeutics »

Akari Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

$5.28

0.12 (2.33%)

07:17
06/27/17
06/27
07:17
06/27/17
07:17
Recommendations
Akari Therapeutics analyst commentary at Canaccord »

Akari Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.